Urol. praxi. 2021;22(1):5-8 | DOI: 10.36290/uro.2020.040

18F-fluciclovine PET/CT in prostate cancer

MUDr. Václav Ptáčník, MUDr. David Zogala
Ústav nukleární medicíny 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice v Praze

Prostate cancer is the most common neoplasm in male population. Despite radical therapy in signifiant number of patients recurrence occures. The recurrence is indicated by PSA level elevation. However for adequate treatment setup localisation of site of reccurece is essential. Fluciclovine is radiotracer used for PET imaging. It is well accumulated in prostate cancer cells. Therefore fluciclovine PET/CT stands for sensititive reccurence localisation method in patients suffering from prostate cancer. In this paper we summarize the use of fluciclovine PET/CT in recurrent prostate cancer patients.

Keywords: PET, fluciclovine, prostate cancer.

Received: June 30, 2020; Revised: September 29, 2020; Accepted: September 29, 2020; Prepublished online: September 29, 2020; Published: April 15, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ptáčník V, Zogala D. 18F-fluciclovine PET/CT in prostate cancer. Urol. praxi. 2021;22(1):5-8. doi: 10.36290/uro.2020.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Novotvary 2016 ČR [online]. Praha: Ústav zdravotnických informací a statistiky ČR [cit. 20. 5. 2020]. Dostupné z: https://www.uzis.cz/sites/default/files/knihovna/novotvary2016.pdf.
    2. Grimm P, Billiet I, Bostwick D, et. al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International 2012; 109: 22-29. doi: 10.1111/j.1464-410X.2011.10827.x. Go to original source... Go to PubMed...
    3. Oka S, Okudaira H, Ono M, et al. Differences in Transport Mechanisms of trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Inflammation, Prostate Cancer, and Glioma Cells: Comparison with l-[Methyl-11C]Methionine and 2-Deoxy-2-[18F]Fluoro-d-Glucose. Molecular Imaging and Biology 2014; 16(3): 322-329. DOI: 10.1007/s11307-013-0693-0. ISSN 1536-1632. Dostupné také z: http://link.springer.com/10.1007/s11307-013-0693-0. Go to original source... Go to PubMed...
    4. Mcparland BJ, Wall A, Johanssons, et al. The clinical safety, biodistribution and internal radiation dosimetry of [18F]fluciclovine in healthy adult volunteers. European Journal of Nuclear Medicine and Molecular Imaging [online] 2013; 40(8): 1256-1264. doi: 10.1007/s00259-013-2403-1. ISSN 1619-7070. Dostupné z: http://link.springer.com/10.1007/s00259-013-2403-1. Go to original source... Go to PubMed...
    5. Gusman M, Aminsharifi JA, Peacock JG, et al. Review of 18F-Fluciclovine PET for Detection of Recurrent Prostate Cancer. RadioGraphics [online] 2019; 39(3): 822-841. DOI: 10.1148/rg.2019180139. ISSN 0271-5333. Dostupné z: http://pubs.rsna.org/doi/10.1148/rg.2019180139. Go to original source... Go to PubMed...
    6. Souhrn údajů o přípravku [online]. [cit. 22-5-2020] Dostupné z: https://www.ema.europa.eu/en/documents/product-information/axumin-epar-product-information_cs.pdf.
    7. Mottet N, Cornford P, Van Den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 [online], Arnhem: European Assotiation of Urology [cit. 22-5-2020]. Dostupné z: https://uroweb.org/guideline/prostate-cancer/.
    8. Nanni C, Zanoni L, Bach-Gansmo T, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging - version 1.0. European Journal of Nuclear Medicine and Molecular Imaging [online] 2020; 47(3): 579-591. [cit. 2020-09-22]. ISSN 1619-7070. Dostupné z: doi: 10.1007/s00259-019-04614-y. Go to original source... Go to PubMed...
    9. Trabulsi EJ, Rumble BR, Jadvar H, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology 2020; 38(17): 1963-1996. ISSN 0732-183X. Dostupné z: doi: 10.1200/JCO.19.02757. Go to original source... Go to PubMed...
    10. Jarolím L, Veselý Š, Schmidt M, et al. Sledování a léčba pacientů po radikální prostatektomii s pozitivními okraji. Ces Urol 2017; 21(2): 139-146.
    11. Odewole OA, Tade FI, Nieh PT, et al. Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT. European Journal of Nuclear Medicine and Molecular Imaging [online] 2016; 43(10): 1773-1783 [cit. 2020-05-28]. Doi: 10.1007/s00259-016-3383-8. ISSN 1619-7070. Dostupné z: http://link.springer.com/10.1007/s00259-016-3383-8. Go to original source... Go to PubMed...
    12. Laudicella R, Albano D, Alongip, et al. 18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers [online] 2019; 11(9). [cit. 2020-05-28]. Doi: 10.3390/cancers11091348. ISSN 2072-6694. Dostupné z: https://www.mdpi.com/2072-6694/11/9/1348. Go to original source... Go to PubMed...
    13. Scarsbrook AF, Bottomley D, Teoh EJ, et al. Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. International Journal of Radiation Oncology*Biology*Physics [online]. 2020; 107(2): 316-324. [cit. 2020-05-28]. Doi: 10.1016/j.ijrobp.2020.01.050. ISSN 03603016. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S0360301620302030. Go to original source... Go to PubMed...
    14. Selnæs KM, Krüger-Stokke B, Elschot M, et al. 18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. European Radiology [online]. 2018; 28(8): 3151-3159.cit. 2020-05-28]. Doi: 10.1007/s00330-017-5213-1. ISSN 0938-7994. Dostupné z: http://link.springer.com/10.1007/s00330-017-5213-1. Go to original source... Go to PubMed...
    15. Nanni C, Zanoni L, Pultrone C, et al. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging [online] 2016; 43(9): 1601-1610. [cit. 2020-06-03]. Doi: 10.1007/s00259-016-3329-1. ISSN 1619-7070. Dostupné z: http://link.springer.com/10.1007/s00259-016-3329-1. Go to original source... Go to PubMed...
    16. Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. The Lancet Oncology [online] 2019; 20(9): 1286-1294. [cit. 2020-06-03]. Doi: 10.1016/S1470-2045(19)30415-2. ISSN 14702045. Dostupné z: https://linkinghub.elsevier.com/retrieve/pii/S1470204519304152. Go to original source... Go to PubMed...
    17. Tan N, Oyoyo U, Bavadian N, et. al. PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology [online] 2020; 296(1): 44-55. [cit. 2020-06-04]. Doi: 10.1148/radiol.2020191689. ISSN 0033-8419. Dostupné z: http://pubs.rsna.org/doi/10.1148/radiol.2020191689. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.